Summary & Overview
HCPCS J1445: Injection, Ferric Pyrophosphate Citrate (Triferic Avnu), 0.1 mg of Iron
HCPCS Level II code J1445 denotes the injection of ferric pyrophosphate citrate solution (Triferic Avnu), measured as 0.1 mg of elemental iron per unit. This code identifies delivery of an intravenous iron therapy product used primarily to manage iron levels in patients receiving chronic treatment that results in iron losses or requirements for parenteral iron. Nationally, accurate coding of IV iron agents like Triferic Avnu matters for clinical tracking, patient safety, and consistent payment processing across payers.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical context for J1445, typical sites of service, and the payer landscape covered. The publication outlines billing considerations, common modifiers reported with infusion and injectable products, and where available, reimbursement benchmarks and coding guidance highlights. Policy updates affecting HCPCS Level II injectable codes and implications for billing workflows are summarized. The report also provides operational notes for documentation and claim submission practices associated with IV iron therapy.
This national summary supports revenue cycle, clinical, and policy stakeholders seeking a focused reference on HCPCS Level II code J1445 and its role in outpatient infusion and dialysis care.
Billing Code Overview
HCPCS Level II code J1445 represents the injection of ferric pyrophosphate citrate solution (Triferic Avnu), with a dosing unit of 0.1 mg of iron. This product is administered intravenously as an iron replacement therapy formulated for patients requiring iron supplementation.
Service Type: Injection / Intravenous iron therapy
Typical Site of Service: Outpatient infusion center, dialysis clinic, or other ambulatory infusion settings where IV iron is administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is a maintenance hemodialysis recipient with chronic kidney disease-related anemia who receives intradialytic iron replacement using ferric pyrophosphate citrate (J1445). Treatment is administered during a hemodialysis session via the dialysis circuit or designated line by a dialysis nurse or nephrology clinician. The workflow: patient arrival and pre-dialysis assessment (vital signs, review labs such as serum ferritin and transferrin saturation), confirmation of indication for intravenous iron during the dialysis session, preparation and verification of J1445 dose per manufacturer guidance, aseptic connection to the extracorporeal circuit, monitoring for infusion-related reactions throughout the session, documentation of lot number and amount administered, and post-dialysis reassessment with documentation of tolerance and scheduling of subsequent doses according to anemia management protocol. The typical site of service is an outpatient dialysis center (end-stage renal disease facility) or hospital-based dialysis unit, with administration occurring concurrently with hemodialysis treatment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the ferric pyrophosphate citrate administration requires substantially greater resources or time due to complexity or complications during dialysis administration. |